Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled trial of eprotirome in heterozygous familial hypercholesterolaemia
2011-001483-21Phase 3Terminated
- Sponsor
- Karo Healthcare AB
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eprotirome in familial hypercholesterolemia (FH) (3 arms), sponsored by Karo Healthcare AB. Primary endpoint: Percent change in LDL cholesterol from baseline to Week 12. Started May 2011; status: terminated.
02
Drugs
eprotirome
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2011-001483-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001483-21.